Press Releases

Circular RNA: The Next Biopharma Revolution Beyond mRNA

Arsenal July 31, 2024

GSK, Flagship Invest $150M in Respiratory and Immunology Programs

Arsenal July 30, 2024

Amylyx Rebounds with GLP-1 Drug Acquisition and Promising Pipeline

Arsenal July 24, 2024

Biotech Layoffs: Navigating Legal Risks During Restructuring

Arsenal July 17, 2024

Eli Lilly’s Tirzepatide: A Potential Game-Changer in Weight-Loss Drugs

Arsenal July 16, 2024

Congress: Renew FDA Pediatric Rare Disease Program

Arsenal July 15, 2024

FDA Rejects Novo’s Once-Weekly Insulin Icodec: 2024 Decision Tracker

Arsenal July 12, 2024

Genentech Reports Results of Tiragolumab Lung Cancer Trial (SKYSCRAPER-06)

Arsenal July 4, 2024

WuXi Scrutiny Opens Doors for India’s Biotech CDMOs

Arsenal July 3, 2024

Gilead’s Trodelvy Faces Setbacks in Trials, Remains Key Cancer Drug

Arsenal July 1, 2024

SNIPR Biome Receives Funding to Develop CRISPR-Based EED Treatment

Arsenal June 28, 2024

Roche’s OCREVUS® SC with ENHANZE® Approved in Europe for Multiple Sclerosis

Arsenal June 25, 2024

NeuroBo’s DA-1726 Outperforms Survodutide in Weight Loss and Lipid-Lowering Pre-Clinical Models

Arsenal June 24, 2024

SpyBiotech Names Keith Dewedoff as New CFO of Vaccine Biotech

Arsenal June 18, 2024

Accelerating Rare Disease Drug Development Through Regulatory Flexibility

Arsenal June 17, 2024

Avidity Biosciences Prices 10.55M Share Public Offering at $38/Share

Arsenal June 14, 2024

Akero Presents Groundbreaking EFX Data at EASL Congress 2024

Arsenal June 10, 2024

Fosigotifator Selected for FDA START Program for Vanishing White Matter Disease

Arsenal June 7, 2024

Boehringer Ingelheim Presents Positive Survodutide Phase 2 Results for MASH at EASL

Arsenal June 6, 2024

SNB-101: Orphan Drug Status for Small Cell Lung Cancer in EU

Arsenal May 31, 2024

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

UK Government’s Controversial Move: Doubling Pharmaceutical Rebates Could Impact NHS Funding and Drug Prices

First Timers Club: Biopharma Launches in 2025 and 2026

Revolutionizing Parkinson’s Treatment: MeiraGTx Partners with AI Startup Hologen to Enhance Gene Therapy Solutions

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA